Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.22) by 68.18 percent. This is a 88.52 percent increase over losses of $(0.61) per share from the same period last year.